The US blood coagulation factor market is supported by the growing need for effective management of hemophilia, von Willebrand disease, and other bleeding disorders. Increasing adoption of recombinant and advanced coagulation factor therapies, along with improvements in diagnosis and personalized treatment, is strengthening demand for specialized products. Continued innovation in longer-acting...